

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 March 2025 (20.03.2025)



(10) International Publication Number
WO 2025/056603 A1

(51) International Patent Classification:

A61K 40/11 (2025.01) *C07K 16/30* (2006.01)
A61K 40/31 (2025.01) *G01N 33/574* (2006.01)
A61K 40/42 (2025.01) *C12N 5/0783* (2010.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2024/075361

(22) International Filing Date:

11 September 2024 (11.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/117992
11 September 2023 (11.09.2023) CN
PCT/CN2024/098418
11 June 2024 (11.06.2024) CN

(71) Applicants: **EXIMMIUM BIOTECHNOLOGIES**

GMBH [DE/DE]; Feodor-Lynen-Strasse 21, 81377 Munich (DE). **EXIMMIUM PTE. LTD.** [SG/SG]; 600 North Bridge Road, #12-02 Parkview Square, Singapore 188778 (SG). **ZENO THERAPEUTICS (SHENZHEN) CO. LTD.** [CN/CN]; 1502-A38, West Block, Tian'an Innovation Technology Plaza (Phase II), Intersection of Binhe Road and Xiangmihu Road, Tian'an Community, Shatou Street, Futian District, Shenzhen, Guangdong 518000 (CN).

(72) Inventors: **GAERTNER, Kathrin**; c/o Eximmium

Biotechnologies GmbH, Feodor-Lynen-Strasse 21, 81377 Munich (DE). **ZHAI, Zhimin**; The Hematology Department, At The Second Affiliated, Hospital Of Anhui Medical University Furong Road 678, The Economic Development Zone, Hefei, Anhui 230601 (CN). **LI, Lietao**; c/o Eximmium Pte. Ltd., 600 North Bridge Road, #12-02 Parkview Square, Singapore 188778 (SG).

(74) Agent: **WEINZIERL, Gerhard** et al.; c/o Schiweck

Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2025/056603 A1

(54) Title: SRRM2 BINDERS FOR TREATING AND DIAGNOSING BLOOD CANCER

(57) Abstract: The present invention provides a pharmaceutical composition comprising an antibody, which binds to human SRRM2 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient for use in a method for the treatment of blood cancer, e.g. MM, PCL or AML, in a patient.